Global CAR T-Cell Therapy Agents Market Growth (Status and Outlook) 2023-2029

Global CAR T-Cell Therapy Agents Market Growth (Status and Outlook) 2023-2029

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.

LPI (LP Information)' newest research report, the “CAR T-Cell Therapy Agents Industry Forecast” looks at past sales and reviews total world CAR T-Cell Therapy Agents sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Therapy Agents sales for 2023 through 2029. With CAR T-Cell Therapy Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Therapy Agents industry.

This Insight Report provides a comprehensive analysis of the global CAR T-Cell Therapy Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR T-Cell Therapy Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR T-Cell Therapy Agents market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Therapy Agents and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Therapy Agents.

The global CAR T-Cell Therapy Agents market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for CAR T-Cell Therapy Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for CAR T-Cell Therapy Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for CAR T-Cell Therapy Agents is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key CAR T-Cell Therapy Agents players cover Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Therapy Agents market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
CD19-targeted
BCMA-targeted

Segmentation by application
Lymphoma
Multiple Myeloma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad

Please note: The report will take approximately 2 business days to prepare and deliver.